Ebola Virus Net is the web resource for anyone interested in ebola. Ebola (Ebola hemorrhagic fever), is a severe, often fatal disease in humans and nonhuman primates such as monkeys, gorillas, and chimpanzees. Ebola is a rare and deadly disease caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There are five identified Ebolavirus species, four of which have caused disease in humans. Ebola is found in several African countries. The first Ebola species was discovered in 1976 near the Ebola River in the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The largest outbreak to date was the epidemic in West Africa, which occurred from December 2013, to January 2016, with 28,646 cases and 11,323 deaths. Other outbreaks in Africa began in the Democratic Republic of the Congo in May 2017 and 2018. In July 2019, the World Health Organization declared the Congo Ebola outbreak a world health emergency.

When an infection does occur in humans, the virus can be spread to others through direct contact with the blood or body fluids of a person who is sick with Ebola, or through contact with objects that have been contaminated with the blood or body fluids of an infected person. Until recent, no vaccines were effective. In December 2016, Ebola was found to be 70–100% prevented by rVSV-ZEBOV vaccine, making it the first proven vaccine against the disease. More than 100,000 people have been vaccinated against Ebola as of 2019.

The objectives of Ebola Virus Net are to be the public and professional information resource for ebola and to serve as a network in the exchange of information and news related to ebola.

• Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus ... - The Lancet
  Thu, 30 Nov 2023 23:33 GMT
• Ebola Virus: Location of Outbreaks, Travel, U.S. Response - Verywell Health
  Thu, 29 Jun 2023 07:00 GMT
• EPI-WIN webinar: Ready to respond to an outbreak of Ebola or Marburg disease - what's new in WHO Infection ... - World Health Organization
  Wed, 11 Oct 2023 07:00 GMT
• What is Marburg virus? 5 things to know about the Ebola-like virus - Nebraska Medicine
  Thu, 13 Jul 2023 07:00 GMT
• Denver Health medical team receives Ebola vaccine - 9News.com KUSA
  Tue, 28 Nov 2023 08:00 GMT
• Molecular mechanism of de novo replication by the Ebola virus polymerase - Nature.com
  Tue, 12 Sep 2023 07:00 GMT
• Burning Man flooding triggers false claims of Ebola outbreak, 'national emergency' - The Associated Press
  Tue, 05 Sep 2023 07:00 GMT
• Fact Check: No evidence Burning Man officials announced Ebola case on X - Reuters
  Wed, 13 Sep 2023 07:00 GMT
• Joining a Global Fight: Students, Faculty Work To Find Ebola, Anthrax Treatment - Cal Poly
  Wed, 27 Sep 2023 07:00 GMT
• NYC Health + Hospitals Leads Multi-Agency Training Exercise for Marburg Virus, an Ebola-Like Disease - NYC Health + Hospitals
  Thu, 03 Aug 2023 07:00 GMT
• Impact of the 2018-2020 Democratic Republic of Congo Ebola epidemic on health system utilization and health ... - Journal of Global Health Reports
  Tue, 10 Oct 2023 07:00 GMT
• How We Used Machine Learning to Investigate Where Ebola May Strike - ProPublica
  Tue, 08 Aug 2023 07:00 GMT
• » A new look inside Ebola's 'viral factories' - La Jolla Institute for Immunology
  Wed, 09 Aug 2023 07:00 GMT
• Sudan Ebola virus (SUDV) outbreak in Uganda, 2022: lessons learnt and future priorities for sub-Saharan Africa - BMC ... - BMC Medicine
  Thu, 13 Apr 2023 07:00 GMT
• OSU integrative biology team uses machine learning in newly published Ebola virus research - Oklahoma State University
  Mon, 25 Sep 2023 07:00 GMT

• PRO/AH/EDR> Ebola update (44): Burkina Faso ex Cote d'Ivoire, 2nd case, NOT
  Mon, 30 Aug 2021 11:01:25 -0400
  Ebola -- Burkina Faso
  On 22 Aug 2021, the Ministry of Health informed the population of the admission to the Medical Emergencies of the Bogodogo University Hospital (CHU-B) of a 22-year-old patient who had stayed in the Republic of [Cote d'Ivoire]. The diagnostic procedure consisted of sampling analysis at the National Reference Laboratory for Viral Haemorrhagic Fever (LNR-FHV at the Muraz Centre) and the Pasteur Institute of Dakar for confirmation. The results obtained make it possible to permanently rule out

• Financial influence on global risks of zoonotic emerging and re-emerging diseases: an integrative analysis Wed, 06 Dec 2023 06:00:00 -0500
  BACKGROUND: Emerging and re-emerging infectious diseases (EIDs), such as Ebola virus disease and highly pathogenic influenza, are serious threats to human health and wellbeing worldwide. The financial sector has an important, yet often ignored, influence as owners and investors in industries that are associated with anthropogenic land-use changes in ecosystems linked to increased EIDs risks. We aimed to analyse financial influence associated with EIDs risks that are affected by anthropogenic...
• Regulation of Ebola GP conformation and membrane binding by the chemical environment of the late endosome Wed, 06 Dec 2023 06:00:00 -0500
  Interaction between the Ebola virus envelope glycoprotein (GP) and the endosomal membrane is an essential step during virus entry into the cell. Acidic pH and Ca2+ have been implicated in mediating the GP-membrane interaction. However, the molecular mechanism by which these environmental factors regulate the conformational changes that enable engagement of GP with the target membrane is unknown. Here, we apply fluorescence correlation spectroscopy (FCS) and single-molecule Förster resonance...
• Understanding knowledge, attitudes and practices on Ebola Virus Disease: a multi-site mixed methods survey on preparedness in Rwanda Tue, 05 Dec 2023 06:00:00 -0500
  CONCLUSION: Our results show that there was high EVD-related knowledge and awareness among the general population in Rwanda. However, for strong public health awareness, preparedness, and protection, a massive investment should always be made in education about EVD with a special focus on districts neighboring countries where the disease is consistently being reported.
• Systems analysis of the effects of the 2014-16 Ebola crisis on WHO-reporting nations' policy adaptations and 2020-21 COVID-19 response: a systematized review Tue, 05 Dec 2023 06:00:00 -0500
  CONCLUSIONS: The shock of 2014-16 EVD outbreak affected most nations around the world, whether they experienced Ebola cases. We further develop a categorical framework that helps characterised nations previous experiences with this biological catastrophe, providing a means to analyse to what extent that individual nations learned and how these EVD-related changes helped inform their COVID-19 response. Nations that demonstrated EVD-related conditioned learning nations tended to have more...
• Improved uniform persistence for partially diffusive models of infectious diseases: cases of avian influenza and Ebola virus disease Tue, 05 Dec 2023 06:00:00 -0500
  Past works on partially diffusive models of diseases typically rely on a strong assumption regarding the initial data of their infection-related compartments in order to demonstrate uniform persistence in the case that the basic reproduction number $ \mathcal{R}_0 $ is above 1. Such a model for avian influenza was proposed, and its uniform persistence was proven for the case $ \mathcal{R}_0 > 1 $ when all of the infected bird population, recovered bird population and virus concentration in water...
• Performance of a safe and dignified burial intervention during an Ebola epidemic in the eastern Democratic Republic of the Congo, 2018-2019 Mon, 04 Dec 2023 06:00:00 -0500
  CONCLUSIONS: A large-scale, timely and moderately performant SDB service proved feasible during the challenging eastern DRC EVD response. Burial teams that are managed by community actors and operate locally, and supported rather than owned by the Red Cross or other humanitarian organisations, are a promising modality of delivering this pillar of EVD control.
• A Flexible, Quantitative Plasmonic-Fluor Lateral Flow Assay for the Rapid Detection of Orthoebolavirus zairense and Orthoebolavirus sudanense Mon, 04 Dec 2023 06:00:00 -0500
  Filoviruses comprise a family of single-stranded, negative-sense RNA viruses with a significant impact on human health. Given the risk for disease outbreaks, as highlighted by the recent outbreaks across Africa, there is an unmet need for flexible diagnostic technologies that can be deployed in resource-limited settings. Herein, we highlight the use of plasmonic-fluor lateral flow assays (PF-LFA) for the rapid, quantitative detection of an Ebolavirus-secreted glycoprotein, a marker for...
• Development of an EBOV MiniG plus system as an advanced tool for anti-Ebola virus drug screening Mon, 04 Dec 2023 06:00:00 -0500
  The incidence of zoonotic diseases, such as coronavirus disease 2019 and Ebola virus disease, is increasing worldwide. However, drug and vaccine development for zoonotic diseases has been hampered because the experiments involving live viruses are limited to high-containment laboratories. The Ebola virus minigenome system enables researchers to study the Ebola virus under BSL-2 conditions. Here, we found that the addition of the nucleocapsid protein of human coronaviruses, such as severe acute...
• Preparedness for future outbreaks: strengthening surveillance of survivors of Ebola virus disease Sun, 03 Dec 2023 06:00:00 -0500
  No abstract
• Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study Sun, 03 Dec 2023 06:00:00 -0500
  BACKGROUND: The use of specific anti-Ebola virus therapy, especially monoclonal antibodies, has improved survival in patients with Ebola virus disease. We aimed to assess the effect of monoclonal antibodies on anti-Ebola virus antibody responses in survivors of the 2018-20 Ebola outbreak in the Democratic Republic of the Congo.